uncovered that tissue‐resident neutrophils contributed to the failure of PD‐L1 blockade treatment.[19] Moreover, NSCLC patients with different responses to PD‐1 blockade have distinct TME remodeling processes during immunotherapy. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.